According to a press release, the biopharmaceutical company Peregrine Pharmaceuticals, Inc. is reporting a 23.2 month median overall survival (OS) rate among patients with locally advanced or metastatic breast cancer when given the company's oncology product bavituximab, a monoclonal antibody, in combination with carboplatin and paclitaxel.
The results were derived from a single-arm, Phase II trial. It compares favorably to separately published trial results that found a median OS of 16 months when given this same patient population was given carboplatin and paclitaxel.
Peregrine is also evaluating bavituximab in randomized Phase II trials against:
-- Non-small cell lung cancer
-- Pancreatic cancer
-- Hepatitis C virus
-- HER2-negative metastatic breast cancer
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody. According to Peregrine, the drug "represents a new approach to treating cancer. PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor."
Source: Therapeutics Daily
Source: http://www.cancertreatment.net/news/breast-cancer/bavituximab-boosts-overall-survival-breast-cancer
world series game 1 exotic animals exotic animals scott hall lra lra collegeboard
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.